Luye Pharma Group Ltd. (HKG:2186)

Market Cap	11.26B +31.9%
Revenue (ttm)	7.02B +4.1%
Net Income	688.55M +31.1%
EPS	0.18 +26.7%
Shares Out	3.99B
PE Ratio	15.96
Forward PE	14.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,996,560
Average Volume	39,766,413
Open	2.840
Previous Close	2.820
Day's Range	2.800 - 2.860
52-Week Range	1.900 - 4.490
Beta	0.92
RSI	57.90
Earnings Date	Mar 30, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 5,115
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2186

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY